Related Experiment Video
Updated: Nov 21, 2025
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
704
Mnk inhibitors: a patent review
Ahmed M Abdelaziz1, Mingfeng Yu1, Shudong Wang1
1Drug Discovery & Development, Cancer Research Institute, Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Pharmaceutical Patent Analyst
|January 14, 2021
Summary
Pyridone-aminal compounds are promising Mnk inhibitors, with Tomivosertib (eFT508) showing significant cancer activity. This review analyzes recent patents on these Mnk inhibitors for cancer therapy development.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Alterations in mRNA translation significantly impact cellular proteome.
- Phosphorylation of eukaryotic initiation factor 4E by mitogen-activated protein kinase-interacting kinases (Mnks) drives oncogenic protein translation.
- Mnk inhibitors represent a key therapeutic strategy in cancer treatment.
Purpose of the Study:
- To review the development of pyridone-aminal-derived Mnk inhibitors.
- To analyze patent applications for novel Mnk inhibitors filed in the last 5 years.
- To highlight the therapeutic potential of these compounds in oncology.
Main Methods:
- Literature review of scientific articles and patent databases.
- Analysis of chemical structures and biological activities of pyridone-aminal derivatives.
- Focus on patents filed within the last five years.
Main Results:
- The pyridone-aminal scaffold has yielded potent and selective Mnk inhibitors.
- Tomivosertib (eFT508), a pyridone-aminal derivative, is among the first Mnk inhibitors in clinical trials.
- These inhibitors demonstrate significant activity against various solid and hematological cancers.
Conclusions:
- Pyridone-aminal-based Mnk inhibitors are a fruitful area of pharmaceutical research.
- Continued development holds promise for novel cancer therapeutics.
- Tomivosertib exemplifies the clinical success of this scaffold.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
381
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
381
01:26FDA Approved Drugs: Changes to Approved Drugs
84
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
84
02:34Inhibition of Cdk Activity
5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
01:30Enzyme Inhibition
88.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
88.9K
01:23Dipeptidyl Peptidase 4 Inhibitors
363
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
363
01:20Antiepileptic Drugs: Potassium Channel Activators
432
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
432